OREGA Biotech (France)

OREGA Biotech — first-in-class antibodies for cancer immunotherapy

OREGA Biotech discovers and develops first-in-class monoclonal antibodies for cancer immunotherapy. IPH5201 (anti-CD39) is in Phase 2 in early-stage NSCLC.

Company details

Address: Écully, France
Website: orega-biotech.com

Reviews

No reviews yet.

All reviews of OREGA Biotech (France) · Write a review

Domain and WHOIS record

Domain: orega-biotech.com
Registrar: IP Twins SAS
Registered: 15 Jan 2010
Expires: 15 Jan 2027
Record updated: 9 Jan 2026
Name servers: ns1.bdm.microsoftonline.com, ns2.bdm.microsoftonline.com
DNSSEC: Not signed

WHOIS record for orega-biotech.com

Sign up for Signalsant to see verified emails, phone numbers and the full company record.